Loading...
•
Sep 30, 2023
NextCure Q3 2023 Earnings Report
NextCure reported third quarter 2023 financial results and provided a business update.
Key Takeaways
NextCure reported a net loss of $14.3 million for the third quarter of 2023, compared to a net loss of $18.9 million for the same period in 2022. The company's cash, cash equivalents, and marketable securities totaled $118.2 million as of September 30, 2023, which is expected to fund operations into mid-2025.
Phase 1b updates for NC410 and NC762 are expected by year end.
Operational update for NC525 Phase 1a is expected by year end.
LNCB74 (B7-H4 ADC) was selected as the first antibody drug conjugate candidate from the collaboration with LegoChem Biosciences, Inc.
Cash of approximately $118 million is expected to fund operations into mid-2025.
Forward Guidance
NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into mid-2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...